Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

FOUND: Editas medicine s return on capital employed insights - You Need To See This

Benzinga Pro data, Editas Medicine (NASDAQ:EDIT) reported Q1 sales of $6.77 million. Earnings fell to a loss of $50.52 million, resulting in a 21.91% decrease from last quarter. In Q4, Editas Medicine brought in $12.47 million in sales but lost $41.44 million in earnings.

What Is ROCE?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.